To: Dr. Steve Beam, NCIMS Chair

From: Roger Hooi, Appendix N Modification Study Committee, Chair
Roger Tedrick, Appendix N Modification Study Committee, Vice Chair

Subject: Appendix N Modification Committee recommendations related to testing of the tetracycline class of drugs and extension of the Pilot Program beyond December 2018

The start date for testing milk for the tetracycline class of drugs for the Pilot Program was July 1, 2017. Testing will continue until a minimum of 18 months of data can be generated for the Appendix N Modification Study Committee to review and to make recommendations related to future testing for drugs other than beta lactams in our nation’s raw milk supply. This testing portion of the Pilot Program is scheduled to be completed on December 31, 2018.

At that time the Appendix N Modification Study Committee recommends that the requirement of sampling and testing no less than 1 in 15 bulk milk tankers and/or all raw milk supplies that have not been transported in bulk milk tankers for the tetracycline class of drugs be suspended until the data collected from this testing portion of the Pilot Program can be reviewed and recommendations made. However, industry and producer stakeholders may continue to test for the tetracycline class of drugs beyond the December 31, 2018 date utilizing the regulatory framework and the protocols established in Appendix N Section V APPROVED TEST METHODS when utilizing approved tests for initial screening or Appendix N Section VI TEST METHODS FOR NON-BETA LACTAMS RESIDUE TESTING THAT HAVE NOT BEEN EVALUATED BY FDA AND ACCEPTED BY THE NCIMS when utilizing unapproved tests for initial screening. The Appendix N Modification Study Committee will be considering another drug class for continuation of the Pilot Program beyond December 31, 2018.